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A B S T R A C T
Gel-free liquid chromatography mass spectrometry coupled to chemical proteomics is a powerful
approach for characterizing cellular target proﬁles of small molecules. We have previously described a
fast and efﬁcient elution protocol; however, altered target proﬁles were observed. We hypothesised that
elution conditions critically impact the effectiveness of disrupting drug-protein interactions. Thus, a
number of elution conditions were systematically assessed with the aim of improving the recovery of all
classes of proteins whilst maintaining compatibility with immunoblotting procedures. A double elution
with formic acid combined with urea emerged as the most efﬁcient and generically applicable elution
method for chemical proteomics
ã 2015 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The majority of drugs are surprisingly promiscuous, thus a
powerful approach to characterize the cellular target proﬁles of
small molecules is imperative. An acid-based chemical proteomic
elution protocol compatible with gel-free liquid chromatography
mass spectrometry (LCMS) is effective; however, altered target
proﬁles were observed. We have optimised and implemented a
new strategy that decidedly enhanced cognate target elution
efﬁciency. This was evident for both chemical immobilization ofAbbreviations: MS, mass spectrometry; LC, liquid chromatography; LCMS, liquid
chromatography mass spectrometry; iTRAQ, isobaric tags for relative and absolute
quantitation; SDS, sodium dodecyl sulphate; CML, chronic myeloid leukemia; TEA,
triethylamine; HPLC-MS, high-performance liquid chromatography mass spec-
trometry; TEAB, triethylammonium bicarbonate; FA, formic acid; ACN, acetonitrile;
XX-NHS, biotin-biotinamidohexanoyl-6-aminohexanoic acid N-hydroxysuccini-
mide ester; DTT, dithiothreitol; TLCK, N-alpha-tosyl-L-lysinyl-chloromethylketone;
U/FA, 3 M urea and 50 mM FA; B, boiling; dNSAF, distributed normalized spectral
abundance factor; dSAF, spectral abundance factor; uSpC, unique spectral count.
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4.0/).compounds on an inert matrix and also for biotinylated
compounds on avidin-functionalized resins.
2. Introduction
Understanding the molecular mechanisms of drugs is of utmost
importance as this knowledge may guide target-based improve-
ment of lead compounds; whilst revealing off-target effects that
lead to toxicity [1–3]. If chemical entities could be matched to
biological processes at the molecular level throughout the drug
discovery and development process, the attrition rates for tool
compounds and drugs could potentially decrease. Concomitantly,
therapeutic efﬁcacy should also improve. Thus, deciphering the
target spectra of bioactive compounds can lead to exploitation of
the full potential of drug candidates. Some examples where this is
applicable are in aiding the identiﬁcation of novel therapeutic
applications or elucidating side effects [4–7]; and/or pharmaco-
logical tool compounds that are used to dissect complex biological
processes [8]. There is a growing body of data that supports the
notion that the majority of drugs are promiscuous and that the ‘one
drug, one target’ paradigm seldom applies [9]. The more we
understand drug properties, the more we realize that it is not so
much the question of if a compound has off-targets, but how many
there are and how these contribute to the biological effects. Several
methods have been employed in the identiﬁcation of small
molecule-protein interactions, such as chemical proteomics or
gene expression-based methods [3,5,10,11].le under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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phy-based approach that is enabled by modern mass spectrometry
(MS) and bioinformatic capabilities [3,12–17]. There are various
protocols in use, but the most widely-accepted procedure entails
the elution of interacting proteins from a drug-afﬁnity matrix with
sodium dodecyl sulphate (SDS) followed by analysis of the eluate
by one- or two-dimensional SDS-PAGE and in situ tryptic digestion
of the proteins. In most cases, the resultant peptide mixture is
analyzed by nano-liquid chromatography (LC) coupled to nano-
electrospray (ESI) tandem MS[18]. Whereas this gel-based
proteomic workﬂow (often referred to as GeLCMS) has been
highly successful and has led to a number of landmark publications
that describe several important novel drug-protein interactions
[8,19–21], there are also a number of important limitations. These
include high labor demand, high cost, and an increased risk of
keratin contamination as a consequence of multiple sample
handling steps. GeLCMS is also not directly compatible with
quantitative proteomic approaches that utilize post-digestion
chemical labeling with isobaric tags (e.g., iTRAQ, TMT) [22].
Therefore, gel-free proteomic methods are receiving more
widespread interest.
We have recently shown that adaptation of a gel-free approach
resulted in a signiﬁcant reduction in sample preparation and MS
instrument time, and ultimately led to an increase in absolute
numbers of identiﬁed proteins [23]. Target recovery was also
improved such that a 5-fold decrease in the protein input was
enabled without loss of data quality [23]. Furthermore, we have
demonstrated the compatibility of our approach with subsequent
relative quantitative proteomics using iTRAQ labeling [24,25].
Despite these advancements, the method has only been used in a
few studies from our groups [26–30], as there were some questions
raised concerning cognate target recovery (especially for receptor
tyrosine kinases, RTKs) and decreased immunoblot efﬁciency. For
example, the detection of the BCR-ABL fusion oncoprotein, which is
the biochemical hallmark of chronic myeloid leukemia (CML) and a
major drug target of several kinase inhibitors (e.g., imatinib and
dasatinib), was compromised. This observation was apparent with
dot blots and western gel-based immunoblot assays. Therefore, we
hypothesised that elution conditions critically impact the effec-
tiveness of disrupting drug-protein interactions. Subsequently, the
ﬁnal drug-protein proﬁle can be altered. Surprisingly, this aspect is
rarely addressed and often overlooked in biochemical approaches
linked to mass spectrometry-based proteomics. Thus, the ultimate
aim of this current study was to systematically and thoroughly
assess a number of different elution conditions to determine the
best, yet generic, protocol that efﬁciently eluted a broad range of
cognate targets encompassing several protein classes. Dasatinib
was initially selected as the test compound. This drug is a multi-
kinase inhibitor approved for the treatment of patients with
imatinib-resistant CML and BCR-ABL-positive acute lymphoblastic
leukemia (ALL). Dasatinib is not only a potent inhibitor of the large
210 kDa fusion protein BCR-ABL [31], but also of the cytosolic TEC
family kinase BTK [6] and the membrane-bound receptor tyrosine
kinase DDR1 [21]. In addition, we have previously generated a
dasatinib analog suitable for chemical proteomics that we have
validated and successfully employed in different studies [21,32,33].
A number of elution conditions were assessed with the
objective to improve: (i) compatibility with immunoblot analysis,
which is an important quality control; and (ii) the overall recovery
of bona ﬁde targets. The protocol optimised on the coupleable
analog of dasatinib was further extended to a biotinylated
derivative of the drug; and also to a second compound with a
different target proﬁle. Compared to dasatinib, sunitinib [34]
inhibits a complementary fraction of kinases [28]. The drug is an
oral, multi-targeted kinase inhibitor, which has been approved for
treatment of imatinib-resistant gastrointestinal stromal tumor andrenal cell carcinoma. Additionally, sunitinib is in clinical trials for
CML and myelodysplastic syndromes. Sunitinib is a potent
inhibitor of receptor tyrosine kinase c-KIT [35], and the serine/
threonine protein kinase PRKAA1 (AMPK1a) and CAMK2 [36].
Overall, we could show that our optimised elution method brought
a universal improvement in elution efﬁciency with two different
drug-coupling strategies and two different kinase inhibitors.
3. Materials and methods
3.1. Chemicals
All chemicals used were of analytical grade, unless stated
otherwise and obtained from commercial suppliers.
3.2. Biological material
K562 and HEL cells were obtained from DSMZ (Deutsche
Sammlung von Mikroorganismen und Zellkulturen). Antibodies
used were rabbit polyclonal anti-DDR1, anti-BTK (E9) and anti-KIT
(C-19) (Santa Cruz Biotechnology, Santa Cruz, CA); and anti-ABL
(21–63) (generated in house).
3.3. Compounds and immobilization
Dasatinib and sunitinib were purchased from Selleck Biochem
(Houston, Texas Area). c-dasatinib was synthesized by WuXi
PharmaTech (Shanghai, China) [21], and c-sunitinib was obtained
from Indus Biosciences Private Limited (Hyderabad, India) through
Gateway Pharma (Freeland, UK). Compounds were immobilized on
NHS-activated Sepharose 4 Fast low (Amersham Biosciences,
Amersham, UK). Beads were washed with dimethyl sulfoxide
(DMSO) and incubated overnight with 1 mM compound and
100 mM triethylamine (TEA) at room temperature (RT) with
constant agitation. After incubation, the supernatant was analyzed
by high-performance liquid chromatography mass spectrometry
(HPLCMS) in order to determine whether the compound was
completely immobilized. Unreacted functional groups were
subsequently blocked with 0.8 M ethanolamine for at least 8 h
at RT, washed with DMSO and either stored at 4 C in isopropyl
alcohol or used immediately for afﬁnity chromatography. For the
biotinylated drug experiments, c-dasatinib was incubated with
biotin amidohexanoyl-6-aminohexanoic acid N-hydroxysuccini-
mide ester (biotin-XX-NHS, Sigma–Aldrich, St. Louis, MO) in the
presence of TEA overnight at RT with constant agitation. The
supernatant was then analyzed by HPLC-MS for residual reagents
and the reaction yield. Dasatinib coupled to biotin was incubated
with UltraLink immobilized streptavidin plus beads (Pierce,
Rockford, IL) on a roto-shaker for 30 min at 4 C and used for
afﬁnity chromatography.
3.4. Afﬁnity puriﬁcation
The same afﬁnity puriﬁcation protocol was used for c-dasatinib,
c-sunitinib and c-dasatinib-XX-biotin. K562 and HEL cell lysates
were prepared using a lysis buffer comprised of 50 mM Tris–HCl
(pH 7.5), 100 mM NaCl, 0.2% NP-40, 5% glycerol, 1.5 mM MgCl2,
25 mM NaF, 1 mM Na3VO4, 1 mM phenylmethylsulfonyl ﬂuoride
(PMSF), 1 mM dithiothreitol (DTT), 10 mg/mL N-alpha-tosyl-L-
lysinyl-chloromethylketone (TLCK), 1 mg/mL leupeptin, 1 mg/mL
aprotinin, and 10 mg/mL soybean trypsin inhibitor. In order to
minimise sample variability, cell lysates were prepared in large
batches, aliquoted and stored at 80 C until required. Before
application to the pre-equilibrated afﬁnity matrices, cell suspen-
sions were clariﬁed by centrifugation. Lysates (5 and 10 mg total
protein for K562 and HEL, respectively) were incubated with drug-
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the lysates were transferred to 2 mL Bio-Spin disposable chroma-
tography columns (BioRad, Hercules, CA). Columns were washed
with lysis buffer and then with 50 mM HEPES–NaOH buffer (pH
7.5) supplemented with 0.5 mM EDTA (pH 8.0) and 100 mM NaCl.
Retained proteins were eluted in several ways: (i) immediate
elution without incubation; (ii) heat denaturation by boiling (B) at
100 C, either for 5 min or 1 h; and (iii) incubation for 1 h at 57 C or
60 C. As elution agents, the following freshly-prepared stocks
were used: (i) 250 mL 100 mM FA; (ii) 300 mL 6 M urea; (iii) 300 mL
1 M NaCl; (iv) 300 mL 25% CH3CN (acetonitrile, ACN); (v) 300 mL
50% CH3CN; (vi) 250 mL 3 M urea, 50 mM FA (U/FA); (vii) 250 mL
0.5M NaCl, 50 mM FA (NaCl/FA); (viii) 250 mL 50% CH3CN, 50 mM
FA (ACN/FA); (ix) HEPES buffer; and (x) 30 mL sodium dodecyl
sulfate (SDS) sample buffer (Laemmli buffer) combined with
boiling for 4 min. In some cases, a double elution procedure was
applied (denoted as .2). After elution with a given agent (e.g., FA or
U/FA), the eluate was collected in a glass vial and re-loaded onto
the drug-afﬁnity matrix and the ﬂow-through collected a second
time. On any occasion where FA was used either as a single agent or
in combination with other components, proteins were eluted into a
glass vial containing either 62.5 mL (FA elution alone) or 31.25 mL
(combinations with FA) 1 M triethylammonium bicarbonate
(TEAB) to neutralize the acidic eluate. Whenever FA was not used,
retained proteins were eluted directly into a glass vial using a
higher volume of eluting agent to maintain the same ﬁnal volume
for all eluates throughout the experiments. For ACN or ACN/FA and
ACN/FA.2, eluted proteins were lyophilised by vacuum centrifuga-
tion and reconstituted in 100 mM TEAB. After elution of the
proteins, the same sample preparation protocols were used
throughout. An aliquot of each eluate (100 mL) was removed for
immunoblot analysis and denatured by boiling for 4 min with
Laemmli buffer. In an initial screen with c-dasatinib where four
selected elution methods were compared to a standard FA
protocol, one biological replicate of each was analysed as technical
duplicates. For the U/FA.2 elution pulldowns with c-dasatinib and
c-sunitinib, ﬁve and two biological replicates were analysed,
respectively. Experiments conducted with c-dasatinib-XX-biotin
consisted of four biological replicates.
3.5. Immunoblot analysis
For the western blot experiments, eluates containing Laemmli
buffer were separated by 1D SDS-PAGE on a 7% polyacrylamide gel.
Blotting was performed for 1 h onto a nitrocellulose transfer
membrane (Protran BA 85, 0.45 mm). After blocking with either 5%
non-fat dry milk or 3% BSA in TBS/Tween, the membrane was
incubated with the primary antibody overnight at 4 C and then for
1 h at RT with the secondary antibody. The signal was detected
using radiographic ﬁlms after incubation with chemi-lumines-
cence detection reagent (ECL normal or ECL plus, GE Healthcare
Bio-Sciences, Uppsala, Sweden). For the dot blot experiments,
eluates containing Laemmli buffer were spotted onto a nitrocellu-
lose membrane using a Bio-Dot apparatus (Biorad, Hercules, CA) as
previously described [37]. The membrane was dried, rehydrated
and analyzed by immune staining. Two 1:5 serial dilutions of the
eluates were used throughout to extend the dynamic range of the
immunoblot signal. This was essential to observe subtle differ-
ences in intensity.
3.6. Solution tryptic digestion of eluted proteins and sample
preparation for liquid chromatography mass spectrometry
Based on the immunoblot experiments, non-acidic eluates were
not analysed by LCMS. The TEAB-neutralized acidic eluates,
however, were reduced with 500 mM DTT at 56 C for 1 h (ﬁnalconcentration DTT approximately 10 mM) and alkylated with 1 M
iodoacetamide for 30 min at room temperature in the dark (ﬁnal
concentration iodoacetamide approximately 55 mM). Depending
on the preceding elution procedure and prior to digestion with
trypsin, samples were diluted with 500 mM TEAB to a concentra-
tion of 250 mM NaCl or 1.5 M urea. All ﬁnal volumes of the various
samples were kept constant throughout. Digestion was performed
with sequencing grade modiﬁed porcine trypsin (Promega,
Madison, WI) overnight at 37 C. Eluates were desalted using
stage tips [38] (3  5% of the digest volume per drug pulldown),
concentrated in a vacuum centrifuge (Eppendorf, Hamburg,
Germany) to approximately 2 mL and then reconstituted with
24 mL 5% FA. All samples were analysed by LCMS as technical
replicates.
3.7. Liquid chromatography mass spectrometry
Mass spectrometry was performed on an linear trap quadrupole
(LTQ) Orbitrap Velos mass spectrometer (ThermoFisher Scientiﬁc,
Waltham, MA) using Xcalibur version 2.1.0 SP1.1160. The instru-
ment was coupled to an Agilent 1200HPLC nanoﬂow systems (dual
pump with one precolumn and one analytical column) (Agilent
Biotechnologies, Palo Alto, CA) via a nanoelectrospray ion source
using a liquid junction (Proxeon, Odense, Denmark). Solvents for
LCMS separation of the digested samples were as follows: solvent A
consisted of 0.4% FA in water and solvent B consisted of 0.4% FA in
70% methanol and 20% isopropanol. Eight microlitres of the tryptic
peptide mixture were automatically loaded from a thermostatted
microautosampler onto a trap column (Zorbax 300SB-C18 5 mm,
5  0.3 mm, Agilent Biotechnologies, Palo Alto, CA) with a binary
pump at a ﬂow rate of 45 mL/min. TFA (0.1%) was used for loading
and washing the precolumn. After washing, the peptides were
eluted by back-ﬂushing onto a 16 cm fused silica analytical column
with an inner diameter of 50 mm packed with C18 reversed phase
material (ReproSil-Pur 120C18-AQ, 3 mm, Dr. Maisch GmbH,
Ammerbuch-Entringen, Germany). The peptides were eluted from
the analytical column with a 27 min gradient ranging from 3 to 30%
solvent B, followed by a 25 min gradient from 30 to 70% solvent B
and, ﬁnally, a 7 min gradient from 70 to 100% solvent B at a
constant ﬂow rate of 100 nL/min [39]. The analyses were
performed in a data-dependent acquisition mode and dynamic
exclusion for selected ions was 60 s. A top 15 collision-induced
dissociation (CID) method was used, and a single lock mass at m/z
445.120024 [Si(CH3)2O)6] [40] was employed. Maximal ion
accumulation time allowed in the CID mode was 50 ms for MSn
in the LTQ and 500 ms in the C-trap. Automatic gain control was
used to prevent overﬁlling of the ion traps and was set to 5000 in
the MSn mode for the LTQ and 106 ions for a full FTMS scan. Intact
peptides were detected 60,000 resolution at m/z 400 [39].
3.8. Data analysis
The acquired raw MS data ﬁles were processed with msconvert
(ProteoWizard Library v2.1.2708) and converted into Mascot
generic format (.mgf) ﬁles. The resultant peak lists were searched
against the human Swiss-Prot database version
v2011.06_20110609 or v2011.12_20111220 (35683 and
35879 sequences, respectively, including isoforms as obtained
from varsplic.pl) with the search engines Mascot (v2.3.02,
MatrixScience, London, U.K.) and Phenyx (v2.5.14, GeneBio,
Geneva, Switzerland). Submission to the search engines was via
a Perl script that performs an initial search with relatively broad
mass tolerances (Mascot only) on both the precursor and fragment
ions (10 ppm and 0.6 Da, respectively). High-conﬁdence pep-
tide identiﬁcations were used to calculate independent linear
transformations for both precursor and fragment ion masses that
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from theoretical. These recalibrating transformations were applied
to all precursor and fragment ions prior to a second search with
narrower mass tolerances (4 ppm and 0.3 Da). One missed
tryptic cleavage site was allowed. Carbamidomethyl cysteine and
oxidized methionine were set as ﬁxed and variable modiﬁcations,
respectively. To validate the proteins, Mascot and Phenyx output
ﬁles were processed by internal parsers. Proteins with 2 unique
peptides above a score T1, or with a single peptide above a score T2,
were selected as unambiguous identiﬁcations. For validated
proteins fulﬁlling either the T1 or T2 criteria, any additional
peptides with a score >T3 were also accepted. For Mascot and
Phenyx, T1, T2, and T3 peptide scores were 16, 40, and 10; and 5.5,
9.5, and 3.5, respectively (P-value <103). For each data set the
validated peptides retrieved by the two algorithms were merged,
any spectral conﬂicts discarded and proteins grouped according to
shared peptides. A false discovery rate (FDR) of <1% and <0.1%
(including the peptides exported with lower scores) was deter-
mined for proteins and peptides by applying the same procedure
against a reversed database. To compare the efﬁciency of the
elution protocols, the distributed normalized spectral abundance
factors (dNSAF) [41] were used as a measure of protein abundance.
dSAFi ¼
1
Li
uSC þ S
NspepðiÞ
k¼1
uSCi
S
NsprotðkÞ
l¼1 uSCl
sSCi;k
  !
ð1Þ
dNSAF ¼ dNSAFi
S
N
l¼1dNSAFl
ð2Þ
Brieﬂy, the distributed spectral abundance factor (dSAF) of
protein i is the weighted sum of the spectral counts divided by
protein length. The weight of unique spectral counts (uSC) is 1,
whereas the weight of spectra for k-th shared peptide (sSCi,k,k = 1,
2. .. Nspep (i)) is the ratio of unique spectral counts of protein i and
the sum of all unique spectral counts for Nsprot(k) proteins that
share k-th peptide. Finally, dSAF is normalized to the total sum of
dSAFs in the speciﬁc LCMS analysis to obtain dNSAF (2). For each
drug, the effect of each elution protocol on the abundance of the
two protein groups was assessed: known targets and interactors
(‘T’), and known contaminants (‘C’: spectrin, actin, myosin,
vimentin, haemoglobin subunits, histone and ribosomal proteins,
heterogeneous ribonuclear proteins, POTE ankyrin domain family
members). Speciﬁcally, the following generalized linear regressionFig. 1. Overview of the experimental approach. (A) Chemical structure of dasatinib and
coupled to sepharose beads via a linker. (B) The overall workﬂow of a chemical proteomodel was applied to dNSAF data:
Ai;j ¼ a0 þ ai þ pGðiÞ;PðjÞ þ qi;PðjÞ þ bBðjÞ þ ej þ di;BðjÞ; ð3Þ
logðdNSAFi;jÞ / NormalðAi;jÞ; ð4Þ
Ii;j / Bernoulli logit1 aAi;j þ b
  
; ð5Þ
where i = 1, 2. .. N and j = 1, 2,... M specify the protein and LCMS
analysis, respectively, and Ai,j is the abundance of i-th protein in the
j-th experiment. Ai,j takes into account the following factors: a0—
the average protein abundance; a0+ ai—the average abundance of
i-th protein; pG(i), P(j)—the average effect of the elution protocol (P
(j)) on a given group of proteins (G(i), either targets or
contaminants); qi,P(j)—the protocol effect on the individual protein;
ej—the normalization term for the j-th LCMS analysis; bB(j) and di,B(j)
account for the global and protein-speciﬁc effects of the B(j)-th
batch of LCMS analyses. The equation (4) links the observed
dNSAFi,j to Ai,j. Bernoulli-logit model (5) is used to properly account
for missing data: protein identiﬁcation (Ii,j= 1) or absence (Ii,j= 0) in
a given experiment is linked to inferred abundance Ai,j, where
parameters a and b are learned from the data.
The model (3)–(5) enables an assessment of how a given
protocol affects the abundance of speciﬁc protein groups (either
targets or contaminants) and individual proteins. At the same time,
these protocol-speciﬁc effects are decoupled from batch-speciﬁc
and individual LCMS data variations. The Bayesian methodology
was adopted and the model (3)–(5) was ﬁt to the experimental
data using STAN [42] to obtain the posterior distributions for all the
model parameters. The posterior distributions for protein group-
speciﬁc protocol effects (pJ,G) were used to estimate the overall
protocol efﬁciencies:
EffðJÞ ¼ ðpJ;T  pJ;CÞ  ðp0;T  p0;CÞ: ð6Þ
That is, Eff(J) reports how much the target proteins (T) are enriched
over the contaminants (C) when using protocol J in comparison to
the 0-th reference protocol (U/FA). It follows from (6) that Eff(J) is
positive for more efﬁcient protocols, and one-sided P-value
PðEffðJÞ  0Þ ð7Þ
provides the statistical signiﬁcance of this hypothesis. c-dasatinib. The latter is the chemically-modiﬁed version of dasatinib that can be
mic experiment.
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4.1. Combining formic acid with denaturing reagents improves
detection of BCR-ABL, DDR1 and BTK by immunoblotting.
The dasatinib analog (Fig. 1A) was coupled to NHS-sepharose
beads and the resultant drug afﬁnity matrix was incubated with
cell extracts from the chronic myelogenous leukemia (CML) cell
line K562 (5 mg protein per pulldown) (Fig. 1B). A number of
different elution reagents and/or conditions were used: (i) 100 mM
formic acid (FA); (ii) 6 M urea (U) [43]; (iii) 1 M NaCl; (iv) 25%
acetonitrile (ACN) [44,45]; (v) 50% ACN [44]; (vi) 3 M urea, 50 mM
FA (U/FA); (vii) 0.5 M NaCl, 50 mM FA (NaCl/FA); (viii) 50% ACN,
50 mM FA (ACN/FA); (ix) HEPES buffer; and (x) 4  SDS sample
buffer (Laemmli buffer). The latter is the traditional method for
gel-based approaches and acts as a control for evaluating the
protein targets of a drug by immunoblot analyses. Elution with
100 mM FA (no incubation of the proteins on the afﬁnity matrices)
is our previously-established, standard elution procedure for gel-
free drug pull-down experiments [23]. All elution protocols
assessed were compared to this ‘standard protocol’. ReagentsFig. 2. Combination of formic acid with denaturing reagents improves elution efﬁcienc
eluted with urea and NaCl. Five-fold serial dilutions from each eluate were also loaded. B
DDR1 dot blots of pulldowns eluted with different concentrations of acetonitrile and comb
1 h incubation of the elution agent on the column. (C) Anti-ABL, anti-DDR1 and anti-BTK
application of the eluate to the column is denoted as .2. Five-fold serial dilutions from eac
blots of pulldowns eluted with same agents and conditions as in (C), B, boiling. (For interp
of this article.)were evaluated at RT or 100 C (B) for 4 min or 1 h. A 1 h incubation
at 57 C and 60 C was also assessed for the urea and ACN elutions,
respectively. It has been previously suggested that the efﬁciency of
protein elution may be improved when incubating at higher
temperatures [44]. In the early stages of the study, one goal was to
establish a reproducible immunoblotting method that would
enable a rapid comparison between selected elution methods. The
dot blot approach allows the direct application of a sample onto a
membrane without prior separation by electrophoresis. Further-
more, proteins are transferred by microﬁltration. This eliminates
any variability caused by the transfer of a protein from a gel. Based
on previous experiments with dasatinib, three antibodies (c-ABL,
DDR1 and BTK) were selected. These proteins are bona ﬁde
dasatinib targets [6,21,31] and belong to different kinase classes:
non-receptor kinases from ABL and TEC family (c-ABL and BTK,
respectively) and receptor tyrosine kinase (DDR1). The differences
between the elution methods were assessed by direct comparison
to the standard elution procedure (Fig. 2). When used as single
agents (Fig. 2A), both 6 M urea (lane 3) and 1 M NaCl (lane 7) gave a
weaker signal for both c-ABL and DDR1 than the standard FA
elution (lane 2). When the samples were boiled (B) for 4 min,y for BCR-ABL, DDR1 and BTK. (A) Anti-ABL and anti-DDR1 dot blots of pulldowns
, boiled; *, 1 h incubation of the elution agent on the column. (B) Anti-ABL and anti-
ined with formic acid. Five-fold serial dilutions from each eluate were also loaded. *,
 dot blots of pulldowns eluted with various elution agents and procedures. Double
h eluate were also loaded. B, boiling. (D) Anti-ABL, anti-DDR1 and anti-BTK western
retation of the references to color in the text, the reader is referred to the web version
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protocol or even slightly improved (lanes 4 and 8, highlighted in
red). A longer incubation time of 1 h (indicated by asterisks) with
urea at 57 C (lane 6) or 100 C (lane 5) did not lead to any visible
improvement in elution efﬁciency. The ACN elution was also weak
(Fig. 2B). Even after a 1 h incubation at RT (lanes 3 and 4) or 60 C
(lanes 5 and 6), ACN as a single elution agent only resulted in a faint
to no signal. Nevertheless, when ACN was combined with FA (lanes
7 and 8, highlighted in red), signal intensity was markedly
improved. Regardless of whether the proteins were immediately
eluted from the drug afﬁnity matrix or after a 1 h incubation period,
the 50% ACN/50 mM FA combination at RT enhanced the elution
and immunoblot efﬁciency to an extent comparable to the
Laemmli control (lane 1). This experimental condition was also
notably improved over the standard FA elution (lane 2).
As the combination of ACN with FA at RT led to a signiﬁcant
improvement in signal intensity, our next step was to evaluate the
effect on protein elution from the drug afﬁnity matrix when all of
the selected reagents were combined with FA. Furthermore, we
reasoned that more proteins could be retrieved if the eluate was
applied to the column twice. Regardless of the reagent chosen, the
eluate was collected, applied to the column a second time, and theFig. 3. Formic acid/urea double elution improved the identiﬁcation of dasatinib targets 
anti-BTK western blots of pulldowns eluted with either FA or U/FA.2, plus the beads s
between FA and U/FA.2. (C) The majority of the cognate kinase targets of dasatinib are m
target of dasatinib, BCR-ABL. An integrated plot showing differences in protein abund
interacting proteins are indicated in the red and blue box plots, respectively. Recovery of a
interacting proteins are less abundant. Five biological replicates were analysed (two te
legend, the reader is referred to the web version of this article.)eluate again collected in a glass vial (denoted as .2 in all ensuing
text). At this point too, an improvement in elution efﬁciency by
boiling the samples was not excluded. Thus, to assess whether
boiling of the samples alone is sufﬁcient to potentiate elution
efﬁciency, HEPES buffer was included in the panel of elution
agents. Dot and western blot analyses of the various eluates for c-
ABL, DDR1 and BTK (Fig. 2C and D) showed that the elution
efﬁciency was markedly enhanced for all three targets when
denaturing agents were combined with formic acid. A double
elution with 50 mM FA combined with either 0.5 M NaCl (NaCl/
FA.2) (Fig. 2C, lane 5, highlighted in red); 3 M urea (U/FA.2) (lane 8,
highlighted in red); and 50% ACN (ACN/FA.2) (lane 10, highlighted
in red) all showed an increase in elution efﬁciency over the
standard procedure where formic acid was used as a single agent
and at a higher concentration of 100 mM (lane 2). Also, it was
observed that in most cases boiling of the samples did not lead to
enhancement of the signal intensity (lanes 6, 9, 11, 12). In some
instances, quite the contrary a weaker signal was apparent
compared to the counterparts that were not boiled (see lane
11 compared to lane 10). Furthermore, boiling of the HEPES eluate
(lane 12) did not result in increased protein recovery. Thus, we
concluded that the combination of a selection of agents with FA isby gel-free liquid chromatography mass spectrometry. (A) Anti-ABL, anti-DDR1 and
equentially eluted with Laemmli buffer. (B) Comparison of the overall abundance
ore abundant with U/FA.2 than FA alone. This is particularly noticeable for the main
ance between the FA alone and the U/FA.2 elution methods. Kinases and kinase-
ll major kinase targets was improved with U/FA.2, whilst the majority of the kinase-
chnical replicates each). (For interpretation of the references to color in this ﬁgure
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selected targets of dasatinib: ABL, receptor tyrosine kinase
DDR1 and the TEC kinase family member, BTK.
BCR-ABL is the main target of dasatinib. Similarly, c-ABL is also
one of the primary targets. As shown in Fig. 2D, both proteins were
recognized by the anti-ABL antibody as evidenced by bands
detected for ABL and BCR-ABL at approximately 140 kDa and
210 kDa, respectively. As mentioned previously, one of the main
issues with the current 100 mM FA standard elution method is the
inability to retrieve ABL proteins with high efﬁciency from the
dasatinib-coupled afﬁnity matrix. This was already apparent from
the dot blot, and is particularly noticeable in the ﬁrst 5-fold
dilution series (Fig. 2C, upper panel, lane 2). Excluding HEPES (lane
12) and U/B (lane 7), the recovery with FA was lower than all the
other elution methods assessed. Even more striking is this
difference on the western blot (Fig. 2D). Here the signal in the
FA eluate is almost completely absent for both BCR-ABL and ABL
(upper panel, lane 2). Conversely, the recovery of these proteins
with U/FA.2 (lane 8, highlighted in red) and ACN/FA.2 (lane 10,
highlighted in red) was even higher than that observed with
Laemmli buffer (lane 1). The difference was not as pronounced
with the two other dasatinib targets, DDR1 and BTK. Nevertheless,
an improvement was still observed when the same set of elution
procedures was used; namely U/FA.2 (middle and lower panels,
lane 8, highlighted in red), U/FA/B (lane 9), ACN/FA.2 (lane 10,
highlighted in red) and ACN/FA/B (lane 11). In addition, NaCl/FA.2
(lane 5, highlighted in red) also showed a slight improvement in
elution efﬁciency. This was particularly noticeable for BCR-ABL and
ABL. An overall comparison of these data showed that on the
immunoblot level, an improvement in the recovery of selected
dasatinib targets was achieved in all instances when formic acid
was combined with a denaturing reagent.
4.2. Combining formic acid with denaturing reagents improved
detection of dasatinib targets by mass spectrometry.
We next asked the question: whether improvement in target
recovery as observed from the immunoblot analyses would also
translate into a higher quality data set by LCMS. Therefore, the
most promising elution methods as determined by immunoblot,
i.e., FA.2, U/FA.2, NaCl/FA.2, and ACN/FA.2 were screened by LCMS
(Supplementary Table S1). The spectral count values were used as
an indicator of target importance; as this represents a combination
of target afﬁnity and abundance [46]. When the average spectral
counts (from two technical replicates) of selected elution methods
were compared for relevant dasatinib targets, we observed that
FA.2 did not show an increase in elution efﬁciency. This led to the
conclusion that the double elution alone is not sufﬁcient to
improve the standard method. Rather, it is the joint effect of the
double elution together with the appropriate combination of
elution reagents. When the other elution methods were compared
to the standard FA protocol, the most striking difference was
observed for BCR-ABL. An almost four-fold increase in average
spectral counts was apparent for the U/FA.2 and ACN/FA.2 elutions
(from 15 spectral counts with FA alone; to 55 and 61.5, respectively,
for the alternate elution methods). Apart from the substantial
increase in the elution efﬁciency of ABL kinases, the data obtained
from the LCMS screen of the proteins eluted with U/FA.2 and ACN/
FA.2 appeared to be comparable to the standard method.
Nonetheless, both elution methods displayed a noticeable
improvement in the immunoblot experiments (Fig. 2C and D).
The U/FA.2 and ACN/FA.2 immunoblot and LCMS data were quite
similar; however, due to the simplicity of the sample preparation
only the U/FA.2 method was investigated further (see below). To
conﬁrm that the observed increase in cognate target recovery was
due to improved elution and not as a consequence of other factorssuch as downstream sample loss, Laemmli buffer was added to the
beads after the proteins had been eluted. The beads were boiled for
5 min and loaded onto a gel together with the eluates. For all three
of the targets (ABL, DDR1 and BTK) assessed by immunoblot, a
clear improvement in elution with U/FA.2 compared to the
standard FA was evident. In support of this observation, residual
protein on the beads was not apparent for U/FA.2 (Fig. 3A).
Conversely, some protein was retained on the beads when FA alone
was used.
To assess both the robustness and consistency of the new
method, ﬁve new cycles of FA and U/FA.2 elution experiments were
conducted and analysed by LCMS (Fig. 3B and C, Supplementary
Table S2). Compared to FA alone (Fig. 3B, light green), elution with
U/FA.2 (red) resulted in higher target recovery. The list of dasatinib
targets consisted of all validated protein kinase targets and indirect
binders of the drug, i.e., the interactors of target kinases
[6,21,29,47–50]. When speciﬁcally assessing the kinase targets of
dasatinib, the target enrichment was even more evident (Fig. 3C).
The majority of the kinases were more abundant in U/
FA.2 compared to the standard FA eluates. Contingent on
previously-published data using gel-based approaches
[21,33,48], the dasatinib targets identiﬁed with the U/
FA.2 elution accurately reﬂected the expected distribution of
primary and secondary interactors. In addition to the dramatic
difference observed with BCR-ABL, ABL2, kinases from the SRC
family (LYN, FYN, YES1 and c-SRC), and the negative regulator c-
SRC kinase (CSK) showed improvement. The TEC family kinases
(BTK and TEC) are prominent interactors of dasatinib [6] and were
also eluted more efﬁciently. Likewise, the receptor tyrosine kinases
DDR1, KIT, EPHB4 and EPHB6 and the serine–threonine kinases
(GAK, MAPK14, MAP3K4) were also identiﬁed with higher spectral
count abundances. RIPK2 was also eluted with higher efﬁciency.
This kinase is a member of the receptor-interacting protein (RIP)
family of serine/threonine protein kinases, and is a known target of
dasatinib that has not been reported with other ABL kinase
inhibitors (e.g., imatinib, nilotinib or ponatinib) [51].
One of the drawbacks of chemical proteomics is that it is
often difﬁcult to distinguish direct from indirect targets. With
the U/FA.2 elution method, however, the contribution from
several non-kinase proteins was reduced (Fig. 3C), e.g., 14-3-
3 proteins, CRKL, UBASH3B, etc. This apparent reduction (as
determined by spectral counts) may reﬂect a decrease in MS
sampling for these proteins due to the concurrent increase in
sampling of the now more efﬁciently eluted true interactors. On
the other hand, the integrin-linked kinase ILK together with the
non-kinase interaction partners LIMS1, LIMS2, PARVB and
RSU1 were consistently observed with notably improved recov-
ery (Fig. 3C). These molecules form a very robust IPP complex
(ILK, PINCH and parvin complex) [52] and thus, do not follow the
same trend as other non-kinase proteins. Rather, these too were
eluted more efﬁciently with U/FA.2. Based on our spectral
counting approach, the data generated from the U/FA.2 elution
method suggested that this particular combination of reagents
may aid in reﬁning the distinction between direct and indirect
interacting proteins.
4.3. U/FA.2 is an elution method of choice for biotinylated compounds
Although the widely-applied chemical immobilization of a
bioactive small molecule on an inert matrix has proven highly-
successful in many chemical proteomic studies; there are a few
drawbacks. Synthesising a coupleable analog of a compound is not
always straightforward. An alternative is to utilise the well-
established biotin/avidin afﬁnity puriﬁcation system. Here, modi-
ﬁcation of a small molecule with a biotin tag enables the non-
covalent capture of drug-protein complexes by (strept) avidin.
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revealed that the standard formic acid-based elution method
did not result in sufﬁcient recovery of proteins when using
biotinylated compounds as the bait; thereby precluding a
successful analysis of such drug target interactions by gel-free
LCMS. We therefore evaluated, if the elution method optimized in
the preceding section would be more successful with respect to the
identiﬁcation of proteins that are enriched with a biotinylated
small molecule. To answer this question, dasatinib was biotiny-
lated (Fig. 4A), attached to streptavidin beads, incubated with
K562 cell lysates (5 mg total protein per experiment) and eluted
using the various methods described earlier (urea, NaCl, ACN), with
or without boiling, in combination with formic acid and with a
double elution. Initial dot blot analyses with an ABL-speciﬁcFig. 4. Double elution with formic acid combined with urea improved the elution of prote
of c-dasatinib for coupling to streptavidin beads. (B) Upper panel: anti-ABL dot blot of th
were used in the c-dasatinib pulldowns. Five-fold serial dilutions from each eluate were a
Lower panel: anti-ABL western blot of pulldowns performed with the positive control (La
for ABL is completely absent when the standard elution with 100 mM FA was used, whi
abundances between FA and U/FA.2. Four biological replicates were analysed (two techni
abundant in U/FA.2 than FA. BCR-ABL was completely absent in the FA pulldowns, but had
elution method. An integrated plot showing differences in abundances between the FA
indicated in the red and blue box plots, respectively. Recovery of all major kinase target
(excluding the IPP complex) are less abundant. (For interpretation of the references to antibody conﬁrmed the feasibility of this molecule as a chemical
proteomic probe as the elution with Laemmli buffer (positive
control) readily recovered ABL proteins (Fig. 4B, lane 1). Strikingly,
but consistent with previous observations [23], no signal was
evident following elution with 100 mM formic acid (Fig. 4B, upper
panel, lane 2). The complete absence of the main target of dasatinib
was also conﬁrmed by western blot (Fig. 4B, lower panel, lane 2). In
contrast, the double elution with urea combined with formic acid
produced an excellent immunoblot signal (Fig. 4B, upper panel,
lane 8, highlighted in red; lower panel, lane 4, highlighted in red)
which was comparable to that obtained with Laemmli buffer (lane
1). LCMS analysis of these eluates (Supplementary Table S3)
strengthened the notion that U/FA.2 is the method of choice to
elute target proteins of biotin-coupled drugs (Fig. 4C). Targetins bound to biotinylated dasatinib. (A) Reaction to produce the biotinylated version
e pulldowns that were eluted with the various elution agents and procedures that
lso loaded. Double application of the eluate to the column is denoted as .2. B, boiled.
emmli), standard (FA) and U/FA (both single and double elution). Immunoblot signal
lst the signal is strong in the U/FA and U/FA.2 pulldowns. (C) Comparison of overall
cal replicates each). (D) The majority of cognate kinase targets of dasatinib are more
 the highest recovery compared to other kinase targets when U/FA.2 was used as the
 and U/FA.2 elution methods is shown. Kinases and kinase-interacting proteins are
s was improved with U/FA.2, whilst the majority of the kinase-interacting proteins
color in this ﬁgure legend, the reader is referred to the web version of this article.)
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to FA alone (green). At the same time, non-target protein
abundance was reduced. In addition, the ratio between target
and non-target proteins was unfavorable for FA alone; whereas for
the U/FA.2 elution, proteins that speciﬁcally interact with dasatinib
were recovered with considerably higher abundance. This was
even more apparent when speciﬁc dasatinib kinase targets were
compared (Fig. 4D). In the FA pulldowns (green), BCR-ABL was
completely absent, but was identiﬁed with high abundance by U/
FA.2 elution (red). All other major targets of dasatinib were
observed when the U/FA.2 elution method was applied, and in all
cases recovery was enhanced compared to the standard method.
Well-known targets that were identiﬁed with a notably higher
abundance were ABL2 and receptor tyrosine kinases (DDR1,
EPHB4). Several SRC and SRC-related kinases (CSK, LYN, FYN,
and c-SRC), SYK, TNK2 (ACK1) and the serine-threonine kinases,
ILK, GAK, MAPK14, MAP3K3 etc. were also observed with higher
abundance (Fig. 4D). Perhaps even more remarkable than the
observations made with the covalent drug immobilization experi-
ments, was that all the secondary interactors (excluding the robust
IPP complex) were identiﬁed with lower abundance (Fig. 4D).
Furthermore, for both drug coupling approaches the increase in
target recovery with U/FA.2 (Fig. 6A, red circles) was particularly
noticeable for tyrosine kinases (including receptor tyrosine
kinases). This observation was emphasised as the target recovery
of RTKs with FA elution method was particularly underwhelming.Fig. 5. Formic acid/urea double elution improved the identiﬁcation of sunitinib targets
modiﬁed version of sunitinib that can be coupled to sepharose beads via a linker. (B) A
stronger compared to the standard elution with 100 mM FA. (C) Comparison of overall a
target proteins with U/FA.2. Two biological replicates were analysed (two technical replic
in U/FA.2 than FA. An integrated plot showing differences in abundances between the FA
indicated in the red and blue box plots, respectively. (For interpretation of the references Differences in target proﬁles between chemically-coupled and
biotinylated drug data were minor (Fig. 6A, two tones of orange).
Moreover, excluding the kinases TESK (not enriched in the U/
FA.2 eluate with c-dasatinib, and not identiﬁed in the c-dasatinib-
biotinylated pulldowns) and ARAF (not enriched in the U/
FA.2 eluate with c-dasatinib-XX-biotin, and not identiﬁed in the
c-dasatinib pulldowns) (Fig. 6A, green); for all dasatinib targets U/
FA.2 was more efﬁcient than FA. Finally, the data led us to conclude
that the observed improvement in the eluted protein proﬁles is not
constrained to a particular class of kinases, but rather, to the overall
increase in target capture (Fig. 6A).
4.4. Elution with the combination of formic acid and urea also
improved identiﬁcation of cognate targets of sunitinib
We next evaluated if the improvements observed with the U/
FA.2 method were unique to dasatinib and target proteins; or if this
would also translate to other drug-protein interactions. Therefore,
sunitinib [34] was selected. Similar to dasatinib, this compound
also has multiple targets, but the proﬁle only displays minimal
overlap with dasatinib [7,28,53]. Afﬁnity chromatography with c-
sunitinib was performed on human erythroid leukemia cells
(Fig. 5A). HEL cells are known to express the RTK c-KIT, which is a
cognate target of sunitinib. The data revealed that both FA and U/
FA.2 elution successfully eluted c-KIT as shown by immunoblotting
(Fig. 5B). Consistent with our previous observations using. (A) Chemical structure of sunitinib and c-sunitinib. The latter is the chemically-
nti-KIT western blot of FA and U/FA.2 pulldowns. Immunoblot signal for U/FA.2 is
bundances between FA and U/FA.2. A strong increase in abundance is observed for
ates each). (D) The majority of cognate kinase targets of sunitinib are more abundant
 and U/FA.2 elution methods is shown. Kinases and kinase-interacting proteins are
to color in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 6. Displayed on the kinome tree in red are the kinases that were observed with a higher abundance in the U/FA.2 elution method. The improvement in eluted protein
proﬁles is not constrained to a particular class of kinases, but rather, the overall increase in target capture. (A) Kinome tree representation for both dasatinib coupling
approaches. Kinases that were recovered with either c-dasatinib or c-dasatinib-XX-biotin are depicted in two different tones of orange, respectively. Kinases that had a higher
recovery with the standard method are displayed in green. (B) In red are the kinases that were observed with a higher abundance in the U/FA.2 elution method in sunitinib
pulldowns. The improvement in eluted protein proﬁles is not constrained to a particular branch and it is mostly reciprocal to dasatinib target distribution. Kinases that had
same recovery are depicted in orange; the ones that had a higher recovery with the standard method are displayed in green. Illustration reproduced courtesy of Cell Signaling
Technology, Inc. (www.cellsignal.com). (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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Furthermore, subsequent LCMS analysis showed that both
methods led to the identiﬁcation of a large number of kinase
targets. The overall elution efﬁciency across all targets, however,
was dramatically enhanced with the urea/formic acid double
elution (Fig. 5C). This improvement was particularly apparent
when the data from other targets of sunitinib was compared, e.g., c-
KIT, PRKAA1 (50-AMP-activated protein kinase 1 alpha, AMPK1a),
or TBK1. As for dasatinib, this improvement was not restricted to a
particular branch of the kinome tree (Fig. 6. A and B). Indirect
binding proteins of kinases, such as regulatory subunits and
multicomponent kinase complex partners of 50-AMP-activated
protein kinase (PRKAB1, PRKAB2, PRKAAG1, PRKAAG2 etc), orTBK1
(TANK, TBKBP1, AZI2) (Fig. 5D) also showed marked improvement.
Furthermore, a number of non-dasatinib kinase targets were
eluted more efﬁciently. These include tyrosine kinases JAK1, FLT4,
NTRK1, PTK2 (FAK), PTK2B (FAK2) etc.; and serine/threonine NAK
kinases (AAK1, BMP2K, GAK), IKK-related kinases (IKBKE, TBK1),
and NEK kinases (NEK2). Calcium/calmodulin dependent protein
kinases such are CAMK2D and CAMK2D were strongly enriched in
the U/FA.2 eluates, in addition to CHEK2, MARK2 and MARK3. This
data showed that the improvement in protein recovery observed
with the U/FA double elution is widely applicable and not just
restricted to a single drug or individual target protein thereof.
5. Conclusion
In this study, we report the successful optimization of chemical
proteomics coupled to gel-free mass spectrometry. By introducing
an adapted double elution method that is beneﬁcial for both
standard drug immobilization protocols and biotinylated drugs, wecould retrieve all cognate targets with higher efﬁciency compared
to our previously preferred method. In general, the combination of
a denaturing agent with formic acid led to an increase in the
elution efﬁciency of drug targets; despite the fact that the
concentration of formic acid was 2-fold lower. The double elution
with a combination of 3 M urea and 50 mM formic acid resulted in
paramount target recovery without comparable enrichment of
non-speciﬁc proteins. This was not constrained neither to a
particular branch of the kinome dendrogram, nor to a single drug.
Furthermore, the success of this elution protocol with biotinylated
compounds offers a promising prospect of also capturing covalent
drug-protein interactions. We believe this adapted elution method
will improve the characterization of cellular target proﬁles of small
molecules. It is mild, rapid, affordable and efﬁcient, and allows a
wide spectrum of proteins to be captured in a single chemical
proteomic experiment.
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